Ref ID: 15157
Author:
S. KRISHNAN-NATESAN, S. SWAMINATHAN, J. CUTRIGHT, C. SUBRAMANIAN, N. GOYAL, R. GEORGE, P. H. CHANDRASEKAR
Author address:
1Wayne State Univ., Detroit, MI, 2John D. Dingell VA Med. Ctr., Detroit, MI.
Full conference title:
50th Annual ICAAC
Date: 12 September 2014
Abstract:
Background: Invasive aspergillosis is associated with a high mortality despite appropriate antifungal therapy. Reports of azole-R continue to emerge from institutions around the world and may contribute to clinical failures. Aim: To evaluate the antifungal susceptibility of A fumigatus at DMC (January 2003- December 2006). Methods: Clinical isolates of Aspergilus spp. were obtained from DMC laboratory, fresh conidial suspensions prepared (2 X104 conidia/ml) and MICs of itraconazole (ITZ), voriconazole (VCZ) and posaconazole (POS) were determined (CLSI M38-A2). Results: A total of 223 isolates of Aspergillus spp. were recovered from sputum (127), bronchoalveolar fluid (37), lung (9), ear (7), sinus (5), blood (3) and others (32): A. fumigatus (174; 78%), A. flavus (20; 9%), A. niger (17; 8%) and others (13; 5%). Frequency of A. fumigatus with azole-MIC ≥ 1 mcg/ml was 24% (’03), 14% (’04), 51% (’05) and 49% (’06). MICs of azoles were high (≥ 1 mcg/ml) in 60/174 isolates of A. fumigatus.;14/14 ITZ-R isolates (MIC ≥ 2 mcg/ml) and 1/6 VCZ-R isolates (MIC >2) were POS-R as well.
Table: A. fumigatus MIC (minimum inhibitory concentration) distribution.
Conclusion: Our study shows a trend in increased frequency of “œazole-R” A. fumigatus compared to our data from the 1990s. Resistance to ITZ and POS were more common; Our data mirror reports from Europe and underscore the need for large scale surveillance of azole-susceptibility in A. fumigatus.
Abstract Number: M-389
Conference Year: 2010
Link to conference website: NULL
New link:
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Teclegiorgis Gebremariam [MS]1, Yiyou Gu [PhD]1, Sondus Alkhazraji [PhD]1, Jousha Quran1, Laura K. Najvar [BS]2, Nathan P. Wiederhold [PharmD]2, Thomas F. Patterson [MD]2, Scott G. Filler [MD]1,3, David A. Angulo (MD)4, Ashraf S. Ibrahim [PhD]1,3*,
2024
91
n/a
-
v
Ruta Petraitiene (US)
2024
90
n/a
-
v
Fabio Palmieri (CH), Junier Pilar
2024
89
n/a
-
v
Evelyne Côté (CA)
2024
88
n/a
-
v
Eliane Vanhoffelen (BE)
2024
87
n/a
-
v
Teclegiorgis Gebremariam, Yiyou Gu, Eman Youssef, Sondus Alkhazraji, Joshua Quran, Nathan P. Wiederhold, Ashraf S. Ibrahim
2024
86
n/a
-
v
Thomas Orasch (DE)
2024
85
n/a
-
v
Julien Alex, Katherine González, Gauri Gangapurwala, Antje Vollrath, Zoltán Cseresnyés, Christine Weber, Justyna A. Czaplewska, Stephanie Hoeppener, Carl-Magnus Svensson, Thomas Orasch, Thorsten Heinekamp, Carlos Guerrero-Sánchez, Marc Thilo Figge, Ulrich S. Schubert, Axel A. Brakhage
2024
84
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
83
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
82
n/a